BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.17.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200908T191500
DTEND;TZID=Africa/Nairobi:20200908T203000
DTSTAMP:20211024T154816Z
CREATED:20210817T105953Z
LAST-MODIFIED:20211024T154816Z
UID:5914-1599592500-1599597000@kesho-kenya.org
SUMMARY:Management of Iron Overload
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Paresh Dave \nSponsor: Novartis \nPresenters: \n\nPeter Oyiro\, Medical Oncologist Kenyatta National Hospital Teaching and Referral Hospital\n\nIron overload is a poly etiologic condition characterized by a moderate to severe increase in the body iron that has or will have negative effects secondary to iron deposition in tissues or body organs. It may be hereditary or acquired. It is important to detect the disease before organ damage occurs. Iron overload affects overall survival partly due to the underlying biology of the disease but also because of the sequelae of iron overload\, including cardiomyopathy\, cardiac events\, liver disease\, and the development of diabetes. For patients with higher serum ferritin levels\, the 100-day post-transplant mortality is worse with inferior overall survival (OS) and a higher rate of graft vs host disease.  Therefore\, iron chelation therapy can improve OS and is effective at reducing serum ferritin levels\, cardiac events\, and diabetes in patients with blood-transfusion-related iron overload. Compliance is highly encouraged to realize successful treatment. The safety profile of each chelator should be evaluated before the initiation of treatment. Patients receiving chemotherapy and who have a drop in blood count parameters require evaluation to find out the causes. Iron studies are required to generate more data. Iron supplementary can be toxic. Patients with severe organ dysfunction can have a combination of iron chelation therapy.  Ferritin levels should be done every 3 months.  Iron chelation OS is not contraindicated in HIV patients with evidence of iron overload.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-iron-overload/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_170945.jpg
END:VEVENT
END:VCALENDAR